Bachem Holding AG (BCHMY)

OTCMKTS · Delayed Price · Currency is USD
8.10
+0.05 (0.62%)
At close: Mar 24, 2026
Market Cap5.92B +31.4%
Revenue (ttm)876.56M +14.8%
Net Income187.64M +23.7%
EPS2.50 +23.8%
Shares Outn/a
PE Ratio31.54
Forward PE26.06
Dividend0.06 (0.80%)
Ex-Dividend DateMay 12, 2025
Volume142
Average Volume1,326
Open8.10
Previous Close8.05
Day's Range8.10 - 8.10
52-Week Range5.50 - 9.40
Beta0.98
RSI52.11
Earnings DateMar 12, 2026

About Bachem Holding AG

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, an... [Read more]

Industry Chemicals
Sector Materials
Founded 1971
Employees 2,363
Stock Exchange OTCMKTS
Ticker Symbol BCHMY

Financial Performance

In 2025, Bachem Holding AG's revenue was 695.07 million, an increase of 14.84% compared to the previous year's 605.26 million. Earnings were 148.79 million, an increase of 23.74%.

Financial numbers in CHF Financial Statements

News

Full Year 2025 Bachem Holding AG Analyst and Media Conference Transcript

Full Year 2025 Bachem Holding AG Analyst and Media Conference Transcript

9 days ago - GuruFocus

Bachem FY25 Earnings Rise; Proposes Dividend Increase; Guides FY26

(RTTNews) - Bachem Holding AG (BCHMY, BCHMF), a Swiss biotechnology company, on Thursday reported higher full-year 2025 net income compared with the previous year, proposed a dividend increase, and pr...

17 days ago - Nasdaq